Zynerba Pharmaceuticals, Inc.
TREATMENT OF SYNGAP1 ENCEPHALOPATHY
Last updated:
Abstract:
The present technology relates to methods of treating SYNGAP1 encephalopathy by transdermally administering an effective amount of cannabidiol (CBD) to the subject, wherein a SYNGAP1 symptom is treated in the subject.
Status:
Application
Type:
Utility
Filling date:
16 Sep 2020
Issue date:
18 Mar 2021